# FDA 483 - Myron Reiff, M.D. - June 27, 2019

Source: https://www.globalkeysolutions.net/records/483/myron-reiff-md/9df20ec6-32b5-4806-9a6c-acc97bea6942

> FDA 483 for Myron Reiff, M.D. on June 27, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Myron Reiff, M.D.
- Inspection Date: 2019-06-27
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Myron H. Reiff, M.D., a clinical investigator in Bellflower, CA, revealed significant deviations from the investigational plan and signed statement of investigator. Findings included backdated subject progress notes, lack of physician care for a screen-failure subject, enrollment of subjects who did not meet inclusion/exclusion criteria, and multiple subjects sharing the same caregiver/informant, contrary to the study protocol.

## Related Officers

- [CSO](https://www.globalkeysolutions.net/people/andrea-a-branche/9ffe9b53-7963-49a6-be4e-25e644f1759f)

Company: https://www.globalkeysolutions.net/companies/myron-reiff-md/289250fc-f1bc-4480-8477-8b2ad90accfa

Office: https://www.globalkeysolutions.net/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9